Intravenous Iron Drugs Market Size, Share, Trends, Growth Outlook

Intravenous Iron Drugs Market is estimated to increase at a growth rate of 9.2% CAGR over the forecast period from 2024 to 2030.

The Intravenous Iron Drugs Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Others), By Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others).

An Introduction to Intravenous Iron Drugs Market in 2024

The Intravenous Iron Drugs market in 2024 addresses a critical need in the management of iron deficiency anemia (IDA), offering rapid and effective replenishment of iron stores in patients with intolerance or inadequate response to oral iron supplementation. Intravenous iron formulations, comprising various iron complexes and carbohydrate-based carriers, provide a well-tolerated and efficient alternative for correcting iron deficits and improving hemoglobin levels in diverse patient populations, including those with chronic kidney disease, inflammatory bowel disease, and heavy menstrual bleeding. The market is witnessing a surge in demand for novel intravenous iron preparations characterized by enhanced safety profiles, reduced infusion reactions, and convenient dosing regimens, thus catering to the evolving clinical needs and preferences of healthcare providers and patients alike.

Intravenous Iron Drugs Market Trend: Rising Demand for Intravenous Iron Drugs in Chronic Kidney Disease Management

A prominent trend in the Intravenous Iron Drugs market is the increasing demand for these drugs in the management of chronic kidney disease (CKD). Intravenous iron therapy is becoming increasingly essential in CKD patients with iron deficiency anemia due to its efficacy in replenishing iron stores and improving hemoglobin levels. As CKD prevalence continues to rise globally, driven by factors such as aging populations and the growing prevalence of risk factors like diabetes and hypertension, the demand for intravenous iron drugs for CKD management is expected to surge.

Market Driver: Growing Incidence of Iron Deficiency Anemia

A key driver fueling the Intravenous Iron Drugs market is the growing incidence of iron deficiency anemia (IDA) worldwide. IDA is a common condition characterized by low levels of iron in the body, leading to reduced red blood cell production and subsequent anemia. Factors such as poor dietary intake, chronic diseases, gastrointestinal disorders, and menstruation contribute to the prevalence of IDA. As awareness about the consequences of untreated IDA increases and healthcare providers prioritize iron repletion therapy, the demand for intravenous iron drugs is expected to grow significantly.

Intravenous Iron Drugs Market Opportunity: Expansion into New Therapeutic Indications Beyond CKD

An opportunity in the Intravenous Iron Drugs market lies in the expansion into new therapeutic indications beyond chronic kidney disease (CKD). While CKD remains a primary indication for intravenous iron therapy, there is potential to explore and develop iron drugs for other conditions associated with iron deficiency anemia, such as heart failure, inflammatory bowel disease, and cancer. By conducting clinical research to demonstrate efficacy and safety in these new therapeutic areas, manufacturers can diversify their product portfolios, tap into new patient populations, and capitalize on unmet medical needs in diverse healthcare settings.

Intravenous Iron Drugs Market Segmentation

By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Intravenous Iron Drugs Market Companies

AbbVie
Americal Reagent
Covis Pharma GmbH
Daiichi Sankyo Company Ltd
Keryx Biopharmaceuticals Inc
Pfizer Inc
Pharmacosmos A/S
Rockwell Medical
Sanofi S.A.
Shield Therapeutics Plc
Vifor Pharma Management Ltd
Zydus Group

 

 

Reasons to Buy the Intravenous Iron Drugs Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Intravenous Iron Drugs Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Intravenous Iron Drugs Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Intravenous Iron Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Intravenous Iron Drugs Market Size Outlook, $ Million, 2021 to 2030
3.2 Intravenous Iron Drugs Market Outlook by Type, $ Million, 2021 to 2030
3.3 Intravenous Iron Drugs Market Outlook by Product, $ Million, 2021 to 2030
3.4 Intravenous Iron Drugs Market Outlook by Application, $ Million, 2021 to 2030
3.5 Intravenous Iron Drugs Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Intravenous Iron Drugs Market Industry
4.2 Key Market Trends in Intravenous Iron Drugs Market Industry
4.3 Potential Opportunities in Intravenous Iron Drugs Market Industry
4.4 Key Challenges in Intravenous Iron Drugs Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Intravenous Iron Drugs Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Intravenous Iron Drugs Market Outlook By Segments
7.1 Intravenous Iron Drugs Market Outlook by Segments
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

8 North America Intravenous Iron Drugs Market Analysis And Outlook To 2030
8.1 Introduction to North America Intravenous Iron Drugs Markets in 2024
8.2 North America Intravenous Iron Drugs Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Intravenous Iron Drugs Market size Outlook by Segments, 2021-2030
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

9 Europe Intravenous Iron Drugs Market Analysis And Outlook To 2030
9.1 Introduction to Europe Intravenous Iron Drugs Markets in 2024
9.2 Europe Intravenous Iron Drugs Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Intravenous Iron Drugs Market Size Outlook By Segments, 2021-2030
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

10 Asia Pacific Intravenous Iron Drugs Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Intravenous Iron Drugs Markets in 2024
10.2 Asia Pacific Intravenous Iron Drugs Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Intravenous Iron Drugs Market size Outlook by Segments, 2021-2030
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

11 South America Intravenous Iron Drugs Market Analysis And Outlook To 2030
11.1 Introduction to South America Intravenous Iron Drugs Markets in 2024
11.2 South America Intravenous Iron Drugs Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Intravenous Iron Drugs Market size Outlook by Segments, 2021-2030
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

12 Middle East And Africa Intravenous Iron Drugs Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Intravenous Iron Drugs Markets in 2024
12.2 Middle East and Africa Intravenous Iron Drugs Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Intravenous Iron Drugs Market size Outlook by Segments, 2021-2030
By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie
Americal Reagent
Covis Pharma GmbH
Daiichi Sankyo Company Ltd
Keryx Biopharmaceuticals Inc
Pfizer Inc
Pharmacosmos A/S
Rockwell Medical
Sanofi S.A.
Shield Therapeutics Plc
Vifor Pharma Management Ltd
Zydus Group

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others